Literature DB >> 8318456

Induction of the anti-ergotypic response.

A W Lohse1, T W Spahn, T Wölfel, J Herkel, I R Cohen, K H Meyer zum Büschenfelde.   

Abstract

The injection of syngeneic activated T cells into rodents can induce a T cell response against activation markers of the T cells, ergotopes. The responding anti-ergotypic T cells have been shown to suppress experimental autoimmune encephalomyelitis (EAE). This paper reports the characteristics of the anti-ergotypic response. It was found that irradiated activated T cells were as good as untreated living activated T cells in inducing anti-ergotypic cells in vivo. Glutardialdehyde-fixed (0.3%) cells were poor stimulators in vivo and non-stimulatory in vitro. Dilution of glutardialdehyde to 0.003% before fixation preserved the stimulatory capacity in vitro. Fixation or irradiation of T cells at different times after activation showed that the stimulatory ergotope appears only after more than 12 h of activation. This ergotope is not secreted by activated T cells, but is a structural component of the activated T cell. Injection of solubilized proteins from activated T cells, but not of supernatants from activated T cells, was able to induce an anti-ergotypic response in vivo. In vitro supernatants from activated T cells also were not stimulatory to anti-ergotypic T cells. The anti-ergotypic response could be measured in draining lymph nodes 3 days after injection, reached a maximum after 7-10 days and subsided thereafter. It was earlier and stronger than the anti-idiotypic response. Induction of the response was dose dependent. As few as 100 cells were able to induce a marked anti-ergotypic response. The ease of the induction and the strength of the anti-ergotypic response suggest a physiological role in immunoregulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318456     DOI: 10.1093/intimm/5.5.533

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

Review 1.  Homeostatic control of immunity by TCR peptide-specific Tregs.

Authors:  Vipin Kumar
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Reverse engineering: a model for T-cell vaccination.

Authors:  L A Segel; E Jäger
Journal:  Bull Math Biol       Date:  1994-07       Impact factor: 1.758

3.  Therapeutic effect of ergotope peptides on CIA by down-regulation of inflammatory and Th1/Th17 responses and induction of regulatory T cells.

Authors:  Xiaoyin Niu; Shaohua Deng; Shan Li; Yebin Xi; Chengzhen Li; Li Wang; Dongyi He; Zhaojun Wang; Guangjie Chen
Journal:  Mol Med       Date:  2016-08-30       Impact factor: 6.354

4.  Development of CD4+ T cell lines that suppress an antigen-specific immune response in vivo.

Authors:  L Vieira de Moraes; B Sun; L V Rizzo
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Authors:  A Van der Aa; N Hellings; R Medaer; G Gelin; Y Palmers; J Raus; P Stinissen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

6.  DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.

Authors:  Avishai Mimran; Felix Mor; Pnina Carmi; Francisco J Quintana; Varda Rotter; Irun R Cohen
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 7.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.